Pharmacological updates of nifuroxazide: Promising preclinical effects and the underlying molecular mechanisms

Althagafy, Hanan S.; El-Aziz, Mostafa K. Abd; Ibrahim, Islam; Abd-alhameed, Esraa K.; Hassanein, Emad H.M.

doi:10.1016/j.ejphar.2023.175776

Cited by 7 publications

(2 citation statements)

References 157 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is important to note that the precise mode of action of NFZ may vary depending on the specific microorganism being targeted ( 48 ). Furthermore, research on the mechanism of action of NFZ is ongoing, and further studies may provide additional insights into its exact molecular interactions and pathways ( 49 ).…”

Section: Discussionmentioning

confidence: 99%

The Existing Drug Nifuroxazide as an Antischistosomal Agent: In Vitro , In Vivo , and In Silico Studies of Macromolecular Targets

Roquini,

Mengarda,

Cajas

et al. 2023

Microbiol Spectr

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

The Existing Drug Nifuroxazide as an Antischistosomal Agent: In Vitro , In Vivo , and In Silico Studies of Macromolecular Targets

Roquini,

Mengarda,

Cajas

et al. 2023

Microbiol Spectr

View full text Add to dashboard Cite

show abstract

“…Nifuroxazide is a safe nitrofuran antibacterial drug that is used clinically to treat acute diarrhea and infectious traveler's diarrhea or colitis. Recent studies revealed that nifuroxazide has multiple pharmacological effects, including anticancer, antioxidant, and Frontiers in Pharmacology frontiersin.org anti-inflammatory effects (Althagafy et al, 2023). Nifuroxazide decreased the levels of proinflammatory cytokines, including TGF-β1, TNF-α, IL-1β, and MCP-1, and macrophage infiltration in a UUO rat model.…”

Section: Chemical Agents For Treating Renal Fibrosismentioning

confidence: 99%

The nuclear factor kappa B signaling pathway is a master regulator of renal fibrosis

Ren,

Wang,

Zou

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Renal fibrosis is increasingly recognized as a global public health problem. Acute kidney injury (AKI) and chronic kidney disease (CKD) both result in renal fibrosis. Oxidative stress and inflammation play central roles in progressive renal fibrosis. Oxidative stress and inflammation are closely linked and form a vicious cycle in which oxidative stress induces inflammation through various molecular mechanisms. Ample evidence has indicated that a hyperactive nuclear factor kappa B (NF-ƙB) signaling pathway plays a pivotal role in renal fibrosis. Hyperactive NF-ƙB causes the activation and recruitment of immune cells. Inflammation, in turn, triggers oxidative stress through the production of reactive oxygen species and nitrogen species by activating leukocytes and resident cells. These events mediate organ injury through apoptosis, necrosis, and fibrosis. Therefore, developing a strategy to target the NF-ƙB signaling pathway is important for the effective treatment of renal fibrosis. This Review summarizes the effect of the NF-ƙB signaling pathway on renal fibrosis in the context of AKI and CKD (immunoglobulin A nephropathy, membranous nephropathy, diabetic nephropathy, hypertensive nephropathy, and kidney transplantation). Therapies targeting the NF-ƙB signaling pathway, including natural products, are also discussed. In addition, NF-ƙB-dependent non-coding RNAs are involved in renal inflammation and fibrosis and are crucial targets in the development of effective treatments for kidney disease. This Review provides a clear pathophysiological rationale and specific concept-driven therapeutic strategy for the treatment of renal fibrosis by targeting the NF-ƙB signaling pathway.

show abstract

Nifuroxazide attenuates indomethacin-induced renal injury by upregulating Nrf2/HO-1 and cytoglobin and suppressing NADPH-oxidase, NF-κB, and JAK-1/STAT3 signals

Hassanein,

Abdel-Reheim,

Althagafy

et al. 2023

Naunyn-Schmiedeberg's Arch Pharmacol

View full text Add to dashboard Cite

Pharmacological updates of nifuroxazide: Promising preclinical effects and the underlying molecular mechanisms

Cited by 7 publications

References 157 publications

The Existing Drug Nifuroxazide as an Antischistosomal Agent: In Vitro , In Vivo , and In Silico Studies of Macromolecular Targets

The Existing Drug Nifuroxazide as an Antischistosomal Agent: In Vitro , In Vivo , and In Silico Studies of Macromolecular Targets

The nuclear factor kappa B signaling pathway is a master regulator of renal fibrosis

Nifuroxazide attenuates indomethacin-induced renal injury by upregulating Nrf2/HO-1 and cytoglobin and suppressing NADPH-oxidase, NF-κB, and JAK-1/STAT3 signals

Contact Info

Product

Resources

About